Outcomes of Neoadjuvant Therapy for Rectal Cancer in a Tertiary Asian Institute
NCT ID: NCT05607186
Last Updated: 2022-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
59 participants
OBSERVATIONAL
2011-01-01
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer
NCT06314737
Clinical Relevance of Major Pathologic Regression for Locally Advanced Rectal Cancer
NCT06879197
MRI Features in Neoadjuvant Treatment Decisions for Patients With Rectal Cancer
NCT05609149
Neoadjuvant Radiotherapy Before Surgery for Rectal Cancer, Surgical and Oncological Outcome Analysis, Retrospective Case Control Study in a Single Institute.
NCT06713824
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator
NCT05338866
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
neoadjuvant long course chemoradiotherapy
neoadjuvant long course chemoradiotherapy consist of radiosensitizing 5FU or capecitabine and 50.4 Gy in 28 fractions over 5 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 1 high risk feature on MRI
* Undergo long course neoadjuvant chemoradiotherapy (LCCRT)
Exclusion Criteria
* Patients who undergo short course radiotherapy
* Patients without a repeat MRI after completion of LCCRT
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Singapore General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019/2342
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.